Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.

@article{Hoos2010DevelopmentOI,
  title={Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.},
  author={A. M. Hoos and Ramy Ibrahim and Alan J Korman and Kald Abdallah and David J. Berman and Vafa Shahabi and Kevin Chin and Renzo M. Canetta and Rachel W Humphrey},
  journal={Seminars in oncology},
  year={2010},
  volume={37 5},
  pages={533-46}
}
Identification of cytotoxic T-lymphocyte antigen-4 (CTLA-4) as a key negative regulator of T-cell activity led to development of the fully human, monoclonal antibody ipilimumab to block CTLA-4 and potentiate antitumor T-cell responses. Animal studies first provided insight into the ability of an anti-CTLA-4 antibody to cause tumor regression, particularly in combination regimens. Early clinical studies defined ipilimumab pharmacokinetics and possibilities for combinability. Phase II trials of… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 92 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 71 references

Ipilimumab monotherapy in patients with previously treated , advanced melanoma : a randomized , double - blind , multicenter , phase 2 , dose - ranging study

  • J Wolchok, B Neyns, G Linette
  • Lancet Oncol
  • 2010

Phase II trial of ipilimumab ( IPI ) and paclitaxel / carboplatin ( P / C ) in first - line stage IIIb / IV non - small cell lung cancer ( NSCLC ) [ abstract ]

  • TJ Lynch, IN Bondarenko, A Luft
  • J Clin Oncol ( Meeting Abstracts )
  • 2010

Phase II trial of ipilimumab monotherapy in melanoma patients with brain metastases [ abstract ]

  • DP Lawrence, O Hamid, DF McDermott
  • J Clin Oncol ( Meeting Abstracts )
  • 2010

Similar Papers

Loading similar papers…